Synergistic action of DPIV and APN in the regulation of T cell function

Area of Science:

• Immunology
• Pharmacology
• Cell Biology

Background:

• Alanyl-aminopeptidases (APN) are crucial for human peripheral T cell function.
• Inhibition of APN affects T cell signaling pathways and cytokine production.
• Dipeptidyl peptidase IV (DPIV) inhibition shows similar effects on T cells, suggesting functional synergy with APN.

Purpose of the Study:

• To investigate the functional synergy between APN and DPIV in T cells.
• To evaluate the combined effect of APN and DPIV inhibition on T cell function.
• To explore the therapeutic potential of simultaneous APN and DPIV inhibition for T cell-mediated diseases.

Main Methods:

• In vitro and in vivo studies using human peripheral T cells.
• Application of APN and DPIV inhibitors, alone and in combination.
• Analysis of T cell signaling pathways (MAP kinases, Wnt-pathway).
• Measurement of cytokine production (IL-2, IL-12, TGF-beta1).

Main Results:

• APN inhibition activates MAP kinases and Wnt-pathway, decreases pro-inflammatory cytokines (IL-2, IL-12), and increases immunosuppressive TGF-beta1.
• DPIV inhibition elicits similar T cell functional changes.
• Simultaneous inhibition of APN and DPIV potentiates the anti-inflammatory and immunosuppressive effects.

Conclusions:

• APN and DPIV exhibit functional synergy in regulating T cell responses.
• Combined inhibition of APN and DPIV enhances immunosuppression.
• This dual inhibition strategy is a promising therapeutic approach for autoimmune diseases, inflammation, allergies, and allograft rejection.